Evidence map›Paper›PMID 17940195›Full record

ArticleThe Journal of pharmacology and experimental therapeutics2008

Multidrug resistance proteins and the renal elimination of inorganic mercury mediated by 2,3-dimercaptopropane-1-sulfonic acid and meso-2,3-dimercaptosuccinic acid.

Christy C Bridges, Lucy Joshee, Rudolfs K Zalups

Abstract read
In one paragraph

Article in The Journal of pharmacology and experimental therapeutics, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 65 citations in OpenAlex.

  1. Mercury in Retrograde: The Tale of Toxicity.Case reports in nephrology · 2026
    Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Environmental pollution and kidney diseases.Nature reviews. Nephrology · 2018
    Review
  11. Article
  12. Xenobiotic transporters and kidney injury.Advanced drug delivery reviews · 2017
    Review
  13. Chronic Kidney Disease and Exposure to Nephrotoxic Metals.International journal of molecular sciences · 2017
    Review
  14. Article
  15. Review
  16. The aging kidney and the nephrotoxic effects of mercury.Journal of toxicology and environmental health. Part B, Critical reviews · 2017
    Review
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Christy C BridgesMercer University School of Medicine, Division of Basic Medical Sciences, 1550 College Street, Macon, GA 31207, USA. bridges_cc@mercer.edu
Lucy Joshee
Rudolfs K Zalups
Mercer University · US

Funding

TRANSPORT-TOXICITY OF INORGANIC MERCURY IN THE NEPHRONR01ES005980 · NIEHS · MERCER UNIVERSITY MACON · PI ZALUPS, RUDOLFS KARLIS · 1993 to 2006
$1.7M
METALLOTHIONEIN, MERCURY AND MONOCYTE ACTIVATIONR01ES011288 · NIEHS · MERCER UNIVERSITY MACON · PI ZALUPS, RUDOLFS KARLIS · 2002 to 2006
$1.5M
MERCURY NEPHROTOXICITY AFTER A REDUCTION OF RENAL MASSR01ES005157 · NIEHS · MERCER UNIVERSITY MACON · PI ZALUPS, RUDOLFS KARLIS · 1995 to 2002
$752k
Role of Multidrug Resistance Proteins 2 and/or 4, and DMPS and DMSA in the RenalR03ES015511 · NIEHS · MERCER UNIVERSITY MACON · PI BRIDGES, CHRISTY C · 2007 to 2008
$145k
MERCURY NEPHROTOXICITY AFTER A REDUCTION OF RENAL MASSR29ES005157 · NIEHS · MERCER UNIVERSITY MACON · PI ZALUPS, RUDOLFS KARLIS · 1988 to 1992
–
TRANSPORT AND TOXICITY OF MERCURY IN THE NEPHRONR55ES005980 · NIEHS · GEORGIA STATE UNIVERSITY · PI BARFUSS, DELON W · 1992 to 1992
–
NIEHS NIH HHS ES015511NIEHS NIH HHS ES05157NIEHS NIH HHS ES05980NIEHS NIH HHS ES11288NIEHS NIH HHS R01 ES005980NIEHS NIH HHS R01 ES011288NIEHS NIH HHS R03 ES015511
6 · The paper itself

Abstract

Current therapies for inorganic mercury (Hg(2+)) intoxication include administration of a metal chelator, either 2,3-dimercaptopropane-1-sulfonic acid (DMPS) or meso-2,3-dimercaptosuccinic acid (DMSA). After exposure to either chelator, Hg(2+) is rapidly eliminated from the kidneys and excreted in the urine, presumably as an S-conjugate of DMPS or DMSA. The multidrug resistance protein 2 (Mrp2) has been implicated in this process. We hypothesize that Mrp2 mediates the secretion of DMPS- or DMSA-S-conjugates of Hg(2+) from proximal tubular cells. To test this hypothesis, the disposition of Hg(2+) was examined in control and Mrp2-deficient TR(-) rats. Rats were injected i.v. with 0.5 mumol/kg HgCl(2) containing (203)Hg(2+). Twenty-four and 28 h later, rats were injected with saline, DMPS, or DMSA. Tissues were harvested 48 h after HgCl(2) exposure. The renal and hepatic burden of Hg(2+) in the saline-injected TR(-) rats was greater than that of controls. In contrast, the amount of Hg(2+) excreted in urine and feces of TR(-) rats was less than that of controls. DMPS, but not DMSA, significantly reduced the renal and hepatic content of Hg(2+) in both groups of rats, with the greatest reduction in controls. A significant increase in urinary and fecal excretion of Hg(2+), which was greater in the controls, was also observed following DMPS treatment. Experiments utilizing inside-out membrane vesicles expressing MRP2 support these observations by demonstrating that DMPS- and DMSA-S-conjugates of Hg(2+) are transportable substrates of MRP2. Collectively, these data support a role for Mrp2 in the DMPS- and DMSA-mediated elimination of Hg(2+) from the kidney.

Indexed as

AnimalsATP-Binding Cassette TransportersChelating AgentsFecesKidneyLiverMaleMercuryRatsRats, WistarSuccimerUnithiolAbcc2 protein, ratATP-Binding Cassette TransportersChelating AgentsMercurySuccimerUnithiol

Identifiers

PMID17940195
PMCPMC2409288
OpenAlexW2123740416

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.